Skip to content
AnalystLens

NBIX · Neurocrine Biosciences

50 filings

10-Q

NBIX 10-Q Quarterly Reports

Neurocrine Biosciences - 50 quarterly reports

Filing record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25
  1. 2026-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2026

    Neurocrine Biosciences, Inc. reported third-quarter 2026 total revenues of $1,122.7 million, up from $794.9 million a year earlier, with net product sales of $1,119.0 million. Net income was $206.5 million, or $1.96 per diluted share, compared with $209.5 million, or $2.04 per diluted share, in the third quarter of 2025. For the first nine months of 2026, total revenues were $2,896.2 million and net income was $548.8 million, or $5.26 per diluted share. The period was shaped by the May 18, 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR. The preliminary consideration transferred was $2,829.9 million, including $2,762.5 million paid to Soleno stockholders, and the acquisition produced $2,191.0 million of net intangible assets and $500.6 million of goodwill. Soleno contributed $106.7 million of net revenues in the third quarter and $161.1 million from the acquisition date through September 30, 2026, and a net loss of $35.1 million over that later period. Product sales growth was driven by CRENESSITY, with third-quarter net sales of $210.8 million versus $98.1 million a year earlier, and by INGREZZA, with third-quarter net sales of $801.5 million versus $686.6 million. Operating expenses rose sharply, with research and development at $351.8 million and selling, general, and administrative expenses at $366.3 million in the quarter. Cash and cash equivalents were $641.5 million at September 30, 2026, and cash flows from operating activities were $677.4 million for the nine months. Cash, cash equivalents and marketable securities totaled $789.7 million, down from $2,543.4 million at December 31, 2025, reflecting the acquisition. The company borrowed and repaid $600.0 million under a new $1.0 billion revolving credit facility, and $1.0 billion of borrowing capacity was available at quarter end. The filing also discloses risks that investors should weigh. A Paragraph IV ANDA filing by Alvogen against VYKAT XR was received in September 2026, and the company sued in October 2026, which triggers a statutory 30-month stay of approval. The FDA identified fluid retention as a potential safety signal for VYKAT XR in a quarterly report published in September 2026. The Department of Justice is investigating INGREZZA sales and marketing, and a securities class action against Soleno is pending. The company repurchased $158.1 million of common stock in the first nine months, with $174.2 million remaining under its 2025 Repurchase Program.

    Nov 2, 2026
  2. 2026-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2026

    Neurocrine Biosciences, Inc. reported second-quarter 2026 total revenues of $959.0 million, up from $687.5 million a year earlier, and net income of $144.4 million, or $1.39 per diluted share, versus $107.5 million and $1.06 in the prior-year quarter. For the first six months, total revenues were $1,773.5 million and net income was $342.3 million, or $3.30 per diluted share. Net product sales of INGREZZA ($716.5 million in the quarter), CRENESSITY ($183.5 million) and the newly acquired VYKAT XR ($54.3 million) drove the results. Selling, general and administrative expense rose to $439.7 million in the quarter, including $96.8 million of acquisition-related expenses for the six months. The most significant event in the period was the May 18, 2026 acquisition of Soleno Therapeutics, Inc. for $53.00 per share in cash, with preliminary total consideration of $2.83 billion and cash paid, net of cash acquired, of $2.36 billion. The purchase price allocation is preliminary, and the company recognized $2.24 billion of developed product rights for VYKAT XR, with goodwill of $494.6 million. Funding came from cash on hand and sales and maturities of available-for-sale debt securities, and the company also borrowed and then repaid $600.0 million under a new $1.0 billion senior secured revolving credit facility. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $481.7 million, down from $2,543.4 million at December 31, 2025, and working capital was $763.0 million. The filing also discloses a Department of Justice civil investigative demand from August 2025 concerning sales and marketing of INGREZZA, which the company is cooperating with, and a securities class action against Soleno that Neurocrine is exposed to as the acquirer. Remaining authorization under the 2025 share repurchase program was $266.3 million at June 30, 2026.

    Jul 31, 2026
  3. 2026-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2026

    Neurocrine Biosciences, Inc. reported first-quarter 2026 net income of $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, in the first quarter of 2025. Total revenues rose to $814.5 million from $572.6 million, driven by net product sales of $811.0 million. INGREZZA net product sales were $656.9 million versus $545.2 million a year earlier, and CRENESSITY net product sales were $153.3 million versus $14.5 million. Operating income was $193.4 million, up from $23.6 million, and the period included a $28.6 million pre-tax gain on the January 2026 sale of Neurocrine Group Limited to Immedica Pharma AB for $63.2 million in cash. Liquidity remained substantial, with total cash, cash equivalents and marketable securities of $2,647.2 million at March 31, 2026, versus $2,543.4 million at December 31, 2025, and working capital of $1,604.4 million. Cash flow from operating activities was $145.8 million. The company repurchased 0.4 million shares for $56.0 million during the quarter and had $276.3 million remaining under its 2025 Repurchase Program. The most significant subsequent event is the pending acquisition of Soleno Therapeutics, Inc. for an equity value of approximately $2.9 billion, through a $53.00 per share cash tender offer commenced April 20, 2026. The Hart-Scott-Rodino waiting period expired April 27, 2026, and the company expects to fund the transaction with cash on hand and expects closing in the second quarter of 2026, subject to a tender of at least a majority of Soleno shares and other customary conditions. The filing also discloses an ongoing U.S. Department of Justice civil investigative demand related to INGREZZA sales and marketing, and patent litigation with Zydus over INGREZZA SPRINKLE.

    May 5, 2026
  4. 2025-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2025

    Neurocrine Biosciences, Inc. reported strong third-quarter 2025 results in its Form 10-Q. Total revenues for the three months ended September 30, 2025 were $794.9 million, up from $622.1 million a year earlier, and net income was $209.5 million, versus $129.8 million. For the first nine months, total revenues were $2.06 billion and net income was $324.9 million. Net product sales of INGREZZA were $686.6 million in the quarter and $1.86 billion year-to-date, while CRENESSITY, launched in December 2024, contributed $98.1 million in the quarter and $165.8 million year-to-date. The company attributed the growth to strong patient demand for INGREZZA, partially offset by lower net price from new market access investments, and to CRENESSITY's launch. Operating expenses rose as the company invested in its commercial organization and pipeline. Research and development expense was $250.0 million in the quarter versus $195.0 million, driven by Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia. Selling, general, and administrative expense was $291.6 million versus $234.3 million. Cash, cash equivalents and marketable securities totaled $2.11 billion at September 30, 2025, and cash flow from operations was $394.3 million for the nine months. The company repurchased $167.7 million of stock in the first nine months under its 2025 program, with $332.3 million remaining. The filing also flags legal and regulatory matters that investors should monitor. These include patent litigation against Zydus over a generic version of INGREZZA SPRINKLE, a civil investigative demand from the U.S. Department of Justice in August 2025 related to INGREZZA sales and marketing, and an FDA untitled letter regarding INGREZZA promotional claims. The filing also notes a Phase 3 study of valbenazine for adjunctive schizophrenia treatment did not meet its primary endpoint, and that customer concentration is high, with four customers representing over 90% of gross product sales.

    Oct 28, 2025
  5. 2025-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2025

    Neurocrine Biosciences, Inc. reported second-quarter 2025 results in this Form 10-Q for the quarter ended June 30, 2025. Total revenues were $687.5 million for the three months ended June 30, 2025, up from $590.2 million a year earlier, driven by net product sales of INGREZZA ($624.4 million) and the newly launched CRENESSITY ($53.2 million). Net income was $107.5 million, or $1.06 per diluted share, compared with $65.0 million, or $0.63 per diluted share, in the prior-year quarter. For the six months ended June 30, 2025, total revenues were $1,260.1 million and net income was $115.4 million, compared with $1,105.5 million and $108.4 million in the first half of 2024. Research and development expense rose to $244.3 million in the quarter from $191.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, and selling, general and administrative expense rose to $286.3 million from $242.0 million. As of June 30, 2025, the company reported total cash, cash equivalents and marketable securities of $1,849.4 million, compared with $1,815.6 million at December 31, 2024. Cash flows from operating activities were $166.8 million for the first six months of 2025, versus $194.9 million a year earlier. During the first six months, the company repurchased $167.7 million of common stock under its 2025 Repurchase Program, leaving $332.3 million available. Management stated that existing capital resources and anticipated product sales are expected to fund operations for at least the next 12 months. The filing also highlights litigation with Zydus over a generic version of INGREZZA SPRINKLE, filed after a Paragraph IV certification in March 2025, and notes that the One Big Beautiful Bill Act, signed July 4, 2025, will be reflected in the third-quarter report as the company continues evaluating its effects.

    Jul 30, 2025
  6. 2025-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2025

    Neurocrine Biosciences, Inc. reported a sharp drop in first-quarter 2025 profitability despite growth in revenue. Total revenues were $572.6 million versus $515.3 million a year earlier, driven by INGREZZA net product sales of $545.2 million (versus $506.0 million) and first CRENESSITY net product sales of $14.5 million following its December 2024 launch. However, operating income fell to $23.6 million from $99.3 million, as research and development expense rose to $263.2 million from $159.4 million, largely due to $37.5 million and $7.5 million milestone expenses payable to Takeda and Xenon, and selling, general and administrative expense rose to $276.5 million from $243.1 million. Net income declined to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share, with an unrealized loss of $30.6 million on equity investments also weighing on results. The balance sheet shows total cash, cash equivalents and marketable securities of $1,758.8 million at March 31, 2025, down from $1,815.6 million at December 31, 2024. Operating cash flow was $64.8 million versus $130.3 million a year earlier, and the company repurchased $150.0 million of common stock during the quarter under its 2025 Repurchase Program, leaving $350.0 million available. Stockholders' equity declined to $2,535.7 million, and accumulated deficit moved to $(5.3) million from retained earnings of $29.2 million. The filing also describes ongoing patent litigation: in April 2025 the company sued Zydus entities over a Paragraph IV ANDA filing for a generic INGREZZA SPRINKLE, and in January 2025 it sued Spruce Biosciences. Management stated it believes no pending claims are likely to have a material adverse effect individually or in the aggregate.

    May 5, 2025
  7. 2024-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2024

    Neurocrine Biosciences, Inc. reported third-quarter 2024 results in its Form 10-Q for the period ended September 30, 2024. Net product sales were $616.6 million for the quarter, up from $491.8 million a year earlier, and INGREZZA net product sales were $612.9 million. Net income rose to $129.8 million from $83.1 million, and diluted EPS was $1.24 versus $0.82. For the first nine months, total revenues were $1,727.6 million and net income was $238.2 million, compared with $102.0 million in the prior-year period. Nine-month results were affected by $138.4 million of charges tied to the May 2024 settlement of the 2024 convertible senior notes, and by $14.0 million of impairment charges on vacated leased office space. Leadership and pipeline developments were significant during the quarter. Kevin Gorman, Ph.D., retired as CEO effective October 11, 2024, and Kyle Gano, Ph.D., succeeded him and joined the Board. The company announced positive Phase 2 topline data for NBI-1117568 in schizophrenia and for NBI-1065845 in major depressive disorder, and FDA accepted NDAs for crinecerfont in classic congenital adrenal hyperplasia with PDUFA dates of December 29 and December 30, 2024. The Phase 2 study of luvadaxistat did not meet its primary endpoint, and the company gave notice to terminate its license agreements with Takeda and Idorsia. At September 30, 2024, cash, cash equivalents and marketable securities totaled $1,871.9 million, and working capital was $1,446.9 million. In October 2024 the Board authorized a share repurchase program of up to $300 million, to be executed through an accelerated share repurchase transaction subject to market conditions. The filing states that existing capital resources are sufficient for at least the next 12 months.

    Oct 30, 2024
  8. 2024-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2024

    Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2024. Net product sales were $583.8 million for the second quarter of 2024 versus $446.3 million a year earlier, driven by INGREZZA net product sales of $579.5 million. Total revenues were $590.2 million and net income was $65.0 million, or $0.63 per diluted share, compared with $95.5 million, or $0.95 per diluted share, in the second quarter of 2023. For the first six months of 2024, net income was $108.4 million, versus $18.9 million a year earlier, which included $143.9 million of acquired in-process R&D expense tied to the Voyager expansion. The six-month 2024 results also reflected $138.4 million of charges associated with conversions of the 2024 convertible senior notes upon their May 2024 maturity, which were settled in cash for $308.8 million. Research and development expense rose to $191.1 million in the second quarter from $145.8 million, and SG&A rose to $242.0 million from $221.8 million, reflecting commercial investment, pre-launch crinecerfont activities, and a $14.0 million impairment charge on vacated leased office space. Cash and cash equivalents were $139.7 million and total cash, cash equivalents and marketable securities were $1,676.7 million at June 30, 2024. Stockholders' equity increased to $2,509.2 million from $2,232.0 million at year-end 2023, and the company stated its existing resources are sufficient for at least the next 12 months. The filing also discloses a planned CEO transition, with Kevin Gorman retiring on October 11, 2024 and Kyle Gano succeeding him, and FDA acceptance of NDAs with Priority Review for crinecerfont for classic congenital adrenal hyperplasia, with PDUFA target dates of December 29, 2024 and December 30, 2024. Management notes that INGREZZA's qualification as a specified small manufacturer under the Medicare Part D discount program may phase in discounts, and that the overall impact on INGREZZA revenues is inherently uncertain.

    Aug 1, 2024
  9. 2024-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2024

    Neurocrine Biosciences, Inc. reported first-quarter 2024 results in its Form 10-Q filed May 1, 2024, with net product sales of $509.0 million, up from $415.3 million in the prior-year quarter, driven primarily by INGREZZA net product sales of $506.0 million, which the filing attributes to strong underlying patient demand and improved gross-to-net dynamics. Total revenues were $515.3 million versus $420.4 million, and the company posted net income of $43.4 million, or $0.42 per diluted share, compared with a net loss of $76.6 million in the first quarter of 2023. Results were affected by $88.7 million of charges tied to the bifurcation of the embedded conversion option of the 2.25% convertible senior notes due May 15, 2024, which the company elected to settle in cash. Acquired in-process R&D fell to $6.0 million from $143.9 million, and operating income was $99.3 million versus an operating loss of $114.2 million. The balance sheet strengthened, with total cash, cash equivalents and marketable securities of $1.91 billion at March 31, 2024, up from $1.72 billion at December 31, 2023, and operating cash flow of $130.3 million. The company stated that existing resources are sufficient for at least the next 12 months and that it has sufficient cash to repay the $170.4 million of remaining 2024 Notes at maturity. Business highlights for April 2024 included positive Phase 2 data for NBI-1065845 in major depressive disorder, two New Drug Applications submitted to the FDA for crinecerfont in classic congenital adrenal hyperplasia, and FDA approval of INGREZZA SPRINKLE. The filing also notes that the company was notified by CMS in April 2024 that it qualified as a "specified small manufacturer" under the Medicare Part D manufacturer discount program, which will phase in the discount. The filing highlights concentration and reimbursement risks: four specialty pharmacy customers represented approximately 94% of total product sales in the quarter, and a majority of current revenue is derived from federal healthcare programs including Medicare and Medicaid. The company's potential future collaboration milestone payments total approximately $17.5 billion across its existing agreements, and it reported 1,448 full-time employees as of March 31, 2024.

    May 1, 2024
  10. 2023-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2023

    Neurocrine Biosciences, Inc. reported third-quarter 2023 total revenues of $498.8 million, up from $387.9 million in the year-earlier quarter, driven by net product sales of $491.8 million, primarily INGREZZA net product sales of $485.7 million on higher prescription demand and increased commercial activities. Net income for the quarter was $83.1 million, compared with $68.5 million a year earlier, and diluted EPS was $0.82 versus $0.69. For the first nine months of 2023, net income was $102.0 million, which included a $143.9 million acquired in-process research and development charge tied to the upfront fee under the expanded Voyager Therapeutics partnership. Total revenues for the nine months were $1,371.9 million. The balance sheet remained strong, with total cash, cash equivalents and marketable securities of $1,549.8 million at September 30, 2023, against total current liabilities of $691.6 million and total stockholders' equity of $2,002.1 million. Management states that existing capital resources, anticipated INGREZZA sales and investment income will be sufficient to fund requirements for at least the next 12 months. The 2024 convertible senior notes, with $170.4 million principal outstanding, became convertible at holders' option from October 1, 2023 through December 29, 2023 because the conditional conversion feature was triggered; the company would settle the principal in cash. Key pipeline and regulatory events in the period included FDA approval of INGREZZA for chorea associated with Huntington's disease in August 2023, FDA acceptance of the INGREZZA oral granules NDA with a PDUFA target date of April 30, 2024, and positive Phase III CAHtalyst top-line data for crinecerfont in adults (September 2023) and pediatrics (October 2023) with classic congenital adrenal hyperplasia. The company also disclosed ongoing ANDA patent litigation over INGREZZA, with trial scheduled for January 2, 2024, and that four customers accounted for approximately 91% of total product revenue for the nine months.

    Oct 31, 2023
  11. 2023-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2023

    Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2023. Total revenues were $452.7 million for the second quarter of 2023, up from $378.2 million a year earlier, driven by net product sales of $446.3 million, mainly from INGREZZA ($439.7 million). Net income for the quarter was $95.5 million, or $0.95 per diluted share, compared with a net loss of $16.9 million in the second quarter of 2022. For the first six months of 2023, the company recorded an operating loss of $40.6 million, which reflects $143.9 million of acquired in-process R&D expense tied to the upfront payment under the expanded Voyager Therapeutics partnership. Net income for the six months was $18.9 million. At June 30, 2023, the company reported total cash, cash equivalents and marketable securities of $1,319.3 million, versus $1,288.7 million at December 31, 2022. Cash flows from operating activities were $54.4 million for the six months, compared with $97.6 million a year earlier. Stockholders' equity rose to $1,853.0 million, and $170.4 million of 2.25% convertible senior notes due May 2024 remained outstanding. Management states that existing capital resources and anticipated INGREZZA sales and investment income will be sufficient to meet funding requirements for at least the next 12 months. The filing also describes ongoing ANDA patent litigation in the District of Delaware over generic versions of INGREZZA, with trial scheduled for January 2, 2024. It discloses that the company has given notice to terminate its ONGENTYS license with BIAL, effective in December 2023 as anticipated. Collaboration milestones tied to partners could total up to $16.9 billion, including up to $6.1 billion for the 2023 Voyager Agreement.

    Aug 1, 2023
  12. 2023-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2023

    Neurocrine Biosciences, Inc. reported a net loss of $76.6 million for the three months ended March 31, 2023, compared with net income of $13.9 million in the prior-year period. Total revenues rose to $420.4 million from $310.6 million, driven by net product sales of $415.3 million, of which INGREZZA accounted for $410.4 million versus $302.6 million a year earlier. The filing attributes the increase to record total prescriptions and higher customer demand. The swing to a loss was primarily due to $143.9 million of acquired in-process R&D expense tied to the upfront payment under the expanded Voyager Therapeutics partnership, along with higher R&D and SG&A spending. The balance sheet shows total cash, cash equivalents and marketable securities of $1,139.2 million at March 31, 2023, down from $1,288.7 million at December 31, 2022. Cash flows from operating activities were negative $125.2 million, reflecting the Voyager upfront payment and continued commercial and clinical investment. The company states that existing capital resources, anticipated INGREZZA sales and investment income are sufficient to fund its requirements for at least the next 12 months. The 2024 Notes had $170.4 million of principal outstanding. The filing also discloses that Neurocrine terminated its license to commercialize ONGENTYS in the United States and Canada, with termination anticipated to be effective in December 2023. In legal matters, the company resolved patent litigation with Teva in the first quarter of 2023, while cases against Lupin, Crystal, Sandoz and Zydus continue, with a trial scheduled for January 2, 2024. Four specialty pharmacy customers represented approximately 81% of total product revenue for the quarter.

    May 3, 2023
  13. 2022-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2022

    Neurocrine Biosciences, Inc.'s Form 10-Q for the quarter ended September 30, 2022 reports total revenues of $387.9 million for the three months ended September 30, 2022, up from $296.0 million a year earlier, with net product sales of $379.3 million, driven by INGREZZA net product sales of $376.4 million. Net income was $68.5 million for the quarter versus $22.5 million in the prior-year period. For the nine months ended September 30, 2022, net income was $65.5 million, which reflected a $70.0 million loss on extinguishment of convertible senior notes recognized in the second quarter, and total revenues were $1,076.7 million. Operating expenses rose, with research and development at $345.8 million and selling, general and administrative expense at $569.8 million for the nine months, reflecting commercial initiatives, expanded clinical programs and higher headcount. The balance sheet shows total cash, cash equivalents and marketable securities of $1,162.0 million at September 30, 2022, compared with $1,272.0 million at December 31, 2021. During the second quarter the company repurchased $210.8 million aggregate principal amount of its 2.25% convertible senior notes due 2024 for $279.0 million in cash, leaving $170.4 million outstanding. Because the conditional conversion feature was triggered, the notes are classified as a current liability, and holders may convert at any time from October 3, 2022 through December 30, 2022. Cash flow from operating activities was $196.4 million for the nine months, compared with $252.3 million a year earlier. Subsequent to the quarter, the company acquired Diurnal Group plc on November 1, 2022 in an all-cash transaction valued at approximately £48.3 million GBP, or approximately $56 million USD, and submitted an sNDA to the FDA for valbenazine in chorea associated with Huntington disease in October 2022. The filing also discloses ongoing ANDA patent litigation against several generic INGREZZA filers, with a Delaware trial currently scheduled for January 2, 2024.

    Nov 1, 2022
  14. 2022-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2022

    Neurocrine Biosciences, Inc. reported a net loss of $16.9 million for the three months ended June 30, 2022, compared with net income of $42.3 million in the prior-year quarter, and a six-month net loss of $3.0 million versus net income of $74.4 million. Total revenues rose to $378.2 million for the quarter from $288.9 million, driven by net product sales of $352.0 million, with INGREZZA net product sales of $349.6 million. The loss was driven mainly by a $70.0 million loss on extinguishment of convertible senior notes tied to the repurchase of $210.8 million of 2024 Notes for $279.0 million in cash, along with research and development expense of $135.9 million (including a $30.0 million milestone expense) and selling, general and administrative expense of $182.8 million. The balance sheet shows cash and cash equivalents of $163.3 million and debt securities available-for-sale of $890.2 million in total ($485.0 million current and $405.2 million noncurrent) at June 30, 2022, with total stockholders' equity of $1,423.4 million. Management states that existing capital resources and anticipated revenues are expected to be sufficient for at least the next 12 months. Outstanding 2024 Notes principal fell to $170.4 million after the repurchase. The company also disclosed that it adopted ASU 2020-06 on January 1, 2022, which increased the carrying amount of the 2024 Notes by $42.2 million and reduced the accumulated deficit by $74.5 million. In August 2022, a Phase IIa study of NBI-827104 in essential tremor did not meet specified endpoints, and the company does not plan to proceed further with that indication. Four pending ANDA-related patent lawsuits over INGREZZA are ongoing, with the consolidated Delaware trial scheduled for January 2, 2024.

    Aug 4, 2022
  15. 2022-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2022

    Neurocrine Biosciences, Inc. reported net income of $13.9 million for the three months ended March 31, 2022, compared with $32.1 million in the same period of 2021, on total revenues of $310.6 million versus $236.6 million. Net product sales rose to $305.0 million from $231.0 million, with INGREZZA net product sales of $302.6 million driven by increased new patient starts. Diluted earnings per share were $0.14, compared with $0.33 a year earlier. Operating income fell to $3.1 million from $31.5 million as total operating expenses increased to $307.5 million from $205.1 million, reflecting higher research and development spending of $102.2 million and selling, general and administrative expense of $200.7 million, including investment in the TD Spotlight-branded direct-to-consumer INGREZZA advertising campaign and an expanded salesforce. Cash flow and liquidity weakened over the quarter. Net cash used in operating activities was $40.5 million, compared with cash provided of $87.3 million a year earlier, and the company cited increased commercial and clinical investment along with an increase in accounts receivable due to extended customer payment terms. Total cash, cash equivalents and marketable securities were $1,205.9 million at March 31, 2022, down from $1,272.0 million at December 31, 2021. The company stated its capital resources and anticipated revenues are sufficient to fund its requirements for at least the next 12 months. The 2.25% convertible senior notes due 2024 had $381.2 million principal outstanding, and the company adopted ASU 2020-06 on January 1, 2022, which increased the carrying amount of those notes by $42.2 million. The filing also highlights litigation and pipeline developments. Several generic filers submitted ANDAs with Paragraph IV certifications against INGREZZA, and the company has sued them in Delaware, with trial scheduled for January 2, 2024. In March 2022, MTPC received Japanese approval for DYSVAL (valbenazine), triggering a $20.0 million milestone payment expected upon first commercial sale in the second quarter of 2022. The company also suspended planned clinical trial activities in Russia and Ukraine following the February 2022 military invasion of Ukraine.

    May 4, 2022
  16. 2021-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2021

    Neurocrine Biosciences, Inc. reported net income of $22.5 million, or $0.23 per diluted share, for the three months ended September 30, 2021, compared with a net loss of $57.6 million in the prior-year quarter. Total revenues rose to $296.0 million from $258.5 million, driven by net product sales of $288.8 million, of which INGREZZA contributed $286.5 million and ONGENTYS $2.3 million. For the nine months, net income was $96.9 million ($0.99 diluted per share) on total revenues of $821.5 million. The prior-year quarter included $118.5 million of acquired in-process R&D tied to the Takeda license, which did not recur in the current quarter. Selling, general and administrative expense rose to $154.6 million for the quarter from $112.5 million, reflecting the May 2021 launch of the INGREZZA "TD Spotlight" direct-to-consumer campaign. The balance sheet strengthened, with cash and cash equivalents of $311.1 million and total debt securities available-for-sale of $968.5 million at fair value, against $381.2 million of principal outstanding on the 2.25% convertible senior notes due 2024. Net cash provided by operating activities was $252.3 million for the nine months, versus $134.0 million a year earlier. Stockholders' equity increased to $1,346.0 million from $1,126.2 million at year-end 2020. The filing also highlights legal and concentration risks. In the second quarter of 2021, four companies filed ANDAs seeking generic versions of INGREZZA, and Neurocrine sued the ANDA filers in July 2021. The company states that two customers represented approximately 85% of total product revenue for the nine months ended September 30, 2021. Management states it believes existing capital resources will be sufficient for at least the next twelve months.

    Nov 1, 2021
  17. 2021-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2021

    Neurocrine Biosciences, Inc. reported second-quarter 2021 total revenues of $288.9 million, compared with $302.4 million in the year-earlier quarter, and net income of $42.3 million, or $0.43 diluted earnings per share, versus $79.6 million, or $0.81 diluted, a year earlier. Net product sales were $266.8 million for the quarter, essentially flat with $267.6 million, which the company attributed to a slowdown in INGREZZA sales volume growth, largely due to COVID-19's impact on customers. Collaboration revenue was $22.1 million, including a $15.0 million milestone tied to Japanese regulatory submission of valbenazine. Selling, general and administrative expense rose to $143.2 million from $96.5 million, reflecting commercial investment including the May 2021 launch of the INGREZZA direct-to-consumer campaign "TD Spotlight", while R&D expense was $74.8 million versus $80.9 million. At June 30, 2021, cash, cash equivalents and debt security investments totaled $1.2 billion, up from $1.0 billion at December 31, 2020. Net cash provided by operating activities was $190.5 million for the six months ended June 30, 2021. Total stockholders' equity increased to $1,279.2 million, and $381.2 million of 2.25% convertible senior notes due 2024 remained outstanding. The filing also discloses that in the second quarter of 2021 the company received Paragraph IV notices from four generic filers (Teva, Lupin, Crystal and Zydus) seeking approval of generic versions of INGREZZA, and that the company filed patent infringement suits in July 2021 in the District of Delaware and, against Zydus, in the District of New Jersey. Management believes no pending claims are likely to have a material adverse effect, though litigation outcomes are unpredictable.

    Aug 3, 2021
  18. 2021-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2021

    Neurocrine Biosciences, Inc. reported net income of $32.1 million, or $0.33 per diluted share, for the three months ended March 31, 2021, compared with $37.4 million, or $0.39 per diluted share, in the prior-year period. Total revenues were $236.6 million versus $237.1 million a year earlier. Product sales, net were $231.0 million, essentially flat against $231.1 million, which the company attributes to a slowdown in INGREZZA sales volume growth, largely due to the impact of COVID-19 on customers. Collaboration revenue was $5.6 million. Operating income fell to $31.5 million from $58.9 million, reflecting higher R&D expense of $73.2 million (up from $58.3 million, including a $6.4 million non-cash share-based compensation charge tied to award modifications) and SG&A of $129.0 million (up from $117.8 million). The balance sheet strengthened over the quarter. Cash and cash equivalents rose to $352.6 million from $187.1 million at December 31, 2020, and cash, cash equivalents and debt security investments totaled $1.1 billion. Net cash provided by operating activities was $87.3 million, compared with $35.5 million a year earlier. Stockholders' equity increased to $1,205.6 million. The company's principal debt is $381.2 million of 2.25% convertible senior notes due May 2024, which the company states it may not redeem before May 15, 2021. The company also began recording income tax expense in 2021 after releasing substantially all of its valuation allowance on December 31, 2020, and the filing states that no federal cash tax is expected in 2021. Pipeline and partnership updates included luvadaxistat not meeting its primary endpoint in the Phase II INTERACT study, with a planned Phase II study for cognitive impairment associated with schizophrenia by the end of 2021, the termination of the NBIb-1817 (VY-AADC) Parkinson's program with Voyager effective August 2, 2021, and MTPC's April 2021 MAA submission in Japan for valbenazine, which triggers a $15.0 million milestone recognized in the second quarter of 2021.

    May 5, 2021
  19. 2020-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2020

    Neurocrine Biosciences, Inc. reported a net loss of $57.6 million, or $0.62 per diluted share, for the three months ended September 30, 2020, compared with net income of $53.8 million, or $0.56 per diluted share, in the prior-year quarter. For the nine months ended September 30, 2020, the company reported net income of $59.4 million, or $0.61 per diluted share, versus $3.0 million, or $0.03 per diluted share, a year earlier. Total revenues were $258.5 million for the quarter and $798.0 million for the nine months, driven by INGREZZA net product sales of $254.1 million for the quarter and $752.8 million for the nine months. The quarterly loss was driven by $118.5 million of acquired in-process R&D tied to the Takeda license upfront payment, alongside R&D expense of $69.1 million and SG&A expense of $112.5 million. The balance sheet shows cash and cash equivalents of $425.3 million at September 30, 2020, and cash and debt securities available-for-sale totaling $1.1 billion. Net cash provided by operating activities was $139.6 million for the nine months. The 2.25% convertible senior notes due 2024, with $517.5 million principal outstanding, became convertible at holders' option from October 1, 2020 through December 31, 2020 after the conditional conversion trigger was met, and are therefore classified as a current liability of $425.0 million net carrying amount. The company states it believes existing capital resources are sufficient for at least the next twelve months. In the filing's risk factors, the company discloses that in November 2020 the Drug Safety Monitoring Board reviewed patient imaging data in the RESTORE-1 Phase II trial of NBIb-1817 (Voyager collaboration) and recommended discontinuing dosing until additional data are reviewed. Key 2020 events included the ONGENTYS approval for Parkinson's disease in April 2020, its commercial launch in late September 2020, the Idorsia and Takeda in-licensing deals, and AbbVie's FDA approval of ORIAHNN in May 2020.

    Nov 9, 2020
  20. 2020-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2020

    Neurocrine Biosciences, Inc. reported net income of $79.6 million, or $0.81 diluted earnings per share, for the three months ended June 30, 2020, compared with $51.3 million, or $0.54 diluted, a year earlier. For the six months ended June 30, 2020, net income was $117.0 million, or $1.20 diluted, versus a net loss of $50.8 million in the prior-year period. Total revenues were $302.4 million for the quarter and $539.5 million for the six months, driven by INGREZZA net product sales of $267.6 million for the quarter and $498.7 million for the six months, plus collaboration revenue that was boosted by a $30.0 million AbbVie regulatory milestone tied to ORIAHNN approval. Operating expenses rose, with R&D at $80.9 million for the quarter (including a $20.0 million milestone on ONGENTYS approval) and SG&A at $96.5 million. Acquired in-process R&D included a $46.0 million charge for the Idorsia license in the second quarter. The company ended the period with cash and cash equivalents of $415.1 million and debt securities available-for-sale of $728.4 million in fair value, with total cash and debt securities described as $1.1 billion. Net cash from operating activities was $157.1 million for the six months. The $517.5 million 2.25% convertible senior notes due 2024 were classified as a current liability because the conversion feature was triggered as of June 30, 2020. Subsequent to the quarter, the company entered into a license agreement with Takeda, paying $120.0 million upfront, with Takeda eligible for up to $1.9 billion in milestones on royalty-bearing products. The filing states that existing funds and cash from operations are adequate to meet needs, while noting that COVID-19 could materially affect revenues, clinical timelines and access to capital.

    Aug 3, 2020
  21. 2020-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2020

    Neurocrine Biosciences, Inc. reported net income of $37.4 million, or $0.39 diluted earnings per share, for the three months ended March 31, 2020, compared with a net loss of $102.1 million, or $1.12 loss per share, in the same period of 2019. Total revenues rose to $237.1 million from $138.4 million, driven primarily by INGREZZA net product sales of $231.1 million (versus $136.4 million). The prior-year quarter included $113.1 million of in-process R&D expensed in connection with the Voyager collaboration, and the current quarter included $16.5 million of unrealized losses on equity investments in Voyager and Xenon. Operating income was $58.9 million for the quarter, against an operating loss of $101.0 million a year earlier. Selling, general and administrative expense rose to $117.8 million and R&D expense to $58.3 million, reflecting higher headcount and continued investment in the Talk About TD campaign and gene therapy programs. Cash and cash equivalents were $187.0 million at March 31, 2020, and cash and debt securities available-for-sale totaled $1.0 billion. Net cash provided by operating activities was $38.2 million, and the company's 2.25% convertible senior notes due 2024 had a principal amount of $517.5 million. The filing states that FDA approved ONGENTYS for adjunctive treatment of Parkinson's disease in April 2020, triggering a $20.0 million milestone payment to BIAL, and that the company plans to launch ONGENTYS later in 2020. The filing also states that COVID-19 has led the company to temporarily pause enrollment in several clinical studies, that management is unable to reliably estimate the duration or extent of the business impact, and that the company currently expects no supply disruption for INGREZZA.

    May 6, 2020
  22. 2019-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2019

    Neurocrine Biosciences, Inc. reported net income of $53.8 million, or $0.56 diluted earnings per share, for the third quarter of 2019, compared with $50.8 million, or $0.52 diluted earnings per share, in the same period of 2018. Total revenues for the quarter were $222.1 million, up from $151.8 million, driven by INGREZZA net product sales of $198.1 million (versus $111.3 million) and $24.0 million of collaboration revenue. For the first nine months of 2019, net income was $3.0 million, or $0.03 per diluted share, after $118.1 million of acquired in-process R&D tied to the Voyager collaboration. The quarter's results were partly offset by a $28.5 million unrealized loss on the company's Voyager equity investment. The balance sheet remained solid, with cash and cash equivalents of $166.6 million and available-for-sale investments that together totaled $875.0 million at September 30, 2019. Against this, the company carried $517.5 million of 2.25% convertible senior notes due 2024, with a net carrying amount of $403.6 million. Net cash provided by operating activities was $49.5 million for the first nine months of 2019. Management stated in the risk factors that existing capital resources, investment income and future strategic alliance payments are expected to be sufficient for at least the next 12 months. Key pipeline and regulatory events disclosed include the September 2019 initiation of the KINECT-HD Phase III study of valbenazine in Huntington's disease chorea, and the FDA's acceptance of an NDA for opicapone in adjunctive Parkinson's disease with a PDUFA target date of April 26, 2020. AbbVie's NDA for elagolix in uterine fibroids was also accepted, with a PDUFA target date in the second quarter of 2020, triggering a $20.0 million milestone payment.

    Nov 4, 2019
  23. 2019-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2019

    Neurocrine Biosciences, Inc. reported net income of $51.3 million, or $0.54 diluted earnings per share, for the second quarter of 2019, compared with a net loss of $5.9 million, or $0.07 per share, in the second quarter of 2018. Total revenues for the quarter were $183.6 million, up from $96.9 million, driven by INGREZZA net product sales of $180.5 million. For the six months ended June 30, 2019, the company reported a net loss of $50.8 million, or $0.56 per share, as it recorded $118.1 million of acquired in-process R&D, mainly the $113.1 million upfront charge tied to the Voyager Therapeutics collaboration. Net cash used in operating activities was $48.3 million for the six-month period, primarily reflecting those Voyager upfront payments. The balance sheet remained solid, with cash and cash equivalents and available-for-sale investments totaling $766.5 million at June 30, 2019, compared with $866.9 million at December 31, 2018. The company's principal debt is $517.5 million of 2.25% convertible senior notes due 2024, with a net carrying amount of $398.5 million. The company also disclosed that the FDA accepted its new drug application for opicapone as an adjunctive therapy in Parkinson's disease, with a PDUFA target action date of April 26, 2020, which triggered a $10.0 million milestone payment to BIAL. The filing highlights ongoing dependence on INGREZZA sales, a limited number of third-party suppliers and contract manufacturers, and key collaborations with AbbVie (ORILISSA, approved for endometriosis pain), Mitsubishi Tanabe, BIAL, and Voyager. The company stated that its existing capital resources, investment income and future strategic alliance payments are expected to be sufficient for at least the next 12 months.

    Jul 29, 2019
  24. 2019-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2019

    Neurocrine Biosciences, Inc. reported a net loss of $102.1 million, or $1.12 per share, for the three months ended March 31, 2019, compared with a net loss of $41.8 million, or $0.47 per share, in the first quarter of 2018. The increase was primarily driven by a $113.1 million acquired in-process research and development charge tied to the January 2019 Voyager Therapeutics collaboration, partially offset by higher INGREZZA net product sales. Total revenues rose to $138.4 million from $71.1 million, with product sales, net of $136.4 million (up from $71.1 million) and collaboration revenue of $2.0 million from sales-based royalties on ORILISSA. Selling, general and administrative expense increased to $87.5 million from $58.6 million, reflecting sales force expansion and the Talk About TD awareness campaign. Liquidity declined over the quarter. Cash, cash equivalents and available-for-sale investments totaled $700.8 million at March 31, 2019, versus $866.9 million at December 31, 2018, and net cash used in operating activities was $112.5 million, reflecting the Voyager IPR&D charge. The company also paid $115.0 million upfront to Voyager and bought $50.0 million of Voyager common stock, which was recorded at $54.7 million. Voyager may receive up to an additional $1.7 billion in milestones across the four programs. The company's $517.5 million of 2.25% convertible senior notes due 2024 are carried at a net $393.4 million, and management states that existing resources, investment income and future strategic alliance payments are sufficient to fund requirements for at least the next 12 months. The filing also flags continued dependence on a limited number of third-party suppliers, the post-marketing requirements for INGREZZA, and the partnership-dependent nature of ORILISSA (partnered with AbbVie). Management also notes that valbenazine's Phase IIb T-Force GOLD study in Tourette syndrome failed to meet its primary endpoint, with next steps still under evaluation.

    Apr 29, 2019
  25. 2018-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2018

    Neurocrine Biosciences, Inc. reported a return to profitability for the third quarter and first nine months of 2018 in this Form 10-Q. Total revenues were $151.8 million for the third quarter, up from $60.8 million a year earlier, and $319.7 million for the first nine months, compared with $67.1 million. Net product sales of INGREZZA reached $111.3 million in the quarter and $279.3 million year to date. The quarter also included a $40.0 million event-based milestone recognized after AbbVie received FDA approval of ORILISSA on July 24, 2018. Net income was $50.8 million ($0.52 diluted per share) for the quarter and $3.0 million ($0.03 diluted per share) for the nine months, versus net losses of $11.1 million and $149.4 million in the prior-year periods. Operating cash flow turned positive, at $50.9 million for the nine months compared with $134.9 million used in the prior-year period. Cash, cash equivalents, restricted cash and investments totaled $826.1 million at September 30, 2018. The 2.25% convertible senior notes due 2024, with $517.5 million principal, were reclassified to current liabilities because the conditional conversion feature was triggered, allowing conversion from October 1 through December 31, 2018. The filing notes that holders may convert at any time during that window, and that settlement may require cash, which could affect liquidity. Management stated that existing capital resources, interest income and alliance payments are sufficient for at least the next 12 months. The filing also states that the company expects higher cost of sales beginning in the fourth quarter of 2018 as it includes the cost of INGREZZA API produced after FDA approval, and that it expects continued increases in expenses as it supports the commercial launch and pipeline.

    Nov 5, 2018
  26. 2018-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2018

    Neurocrine Biosciences, Inc. reported its Form 10-Q for the quarter ended June 30, 2018. Net product sales of INGREZZA (valbenazine) for tardive dyskinesia reached $96.9 million for the second quarter of 2018 and $168.0 million for the first six months, compared with $6.3 million in both periods of 2017, which reflected the April 2017 launch. The company's net loss narrowed to $5.9 million, or $0.07 per share, for the second quarter, versus $60.0 million, or $0.68 per share, a year earlier. For the first six months, net loss was $47.7 million, or $0.53 per share, compared with $138.3 million, or $1.58 per share, in the prior-year period. Operating expenses rose, with SG&A at $119.6 million and R&D at $85.9 million for the six months, reflecting the commercial launch and pipeline progression. As of June 30, 2018, cash and cash equivalents of $166.4 million, short-term investments of $342.3 million and long-term investments of $249.4 million totaled $763.6 million including restricted cash, compared with $767.8 million at December 31, 2017. The company's $517.5 million principal of 2.25% convertible senior notes due 2024 is carried at $378.9 million net of discounts. Net cash used in operating activities narrowed to $18.0 million for the six months from $125.6 million a year earlier. Management states that existing capital resources, together with interest income and future payments under strategic alliances, will be sufficient for at least the next 12 months. Subsequent events include FDA approval on July 24, 2018 of ORILISSA (elagolix) for moderate to severe endometriosis pain, which triggers a $40.0 million event-based payment from AbbVie to the company, to be recognized as revenue in the third quarter of 2018. The filing also states that the Mount Sinai litigation was agreed to be dismissed in its entirety in the third quarter of 2018.

    Jul 31, 2018
  27. 2018-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2018

    Neurocrine Biosciences, Inc. reported its first quarter 2018 results in this Form 10-Q, with the first full quarter of INGREZZA (valbenazine) product sales following FDA approval for tardive dyskinesia in April 2017. Net product sales were $71.1 million for the three months ended March 31, 2018, compared with none in the prior-year quarter. Operating expenses rose to $108.5 million, led by sales, general and administrative expense of $58.6 million (up from $28.1 million) tied to the INGREZZA commercial launch. The net loss narrowed to $41.8 million, or $0.47 per share, from $78.3 million, or $0.90 per share, in the first quarter of 2017, which included a $30 million in-licensing payment to BIAL for opicapone. The balance sheet shows cash and cash equivalents of $175.3 million and total investments of $561.5 million at March 31, 2018, which the MD&A describes as cash, cash equivalents and investments totaling $736.8 million. Convertible senior notes of $374.2 million net carrying amount reflect $517.5 million in principal of 2.25% notes due 2024. Net cash used in operating activities was $38.5 million for the quarter, versus $77.4 million a year earlier. The company states it believes existing resources will be sufficient for at least the next 12 months. The filing also discloses that AbbVie notified the company of a three-month extension to the elagolix NDA review, moving the PDUFA date into the third quarter of 2018. A $10 million milestone was paid to BIAL after the FDA did not require an additional Phase III study for opicapone. The Mount Sinai litigation over the AbbVie collaboration remains pending, with a trial anticipated in the third quarter of 2018.

    Apr 30, 2018
  28. 2017-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2017

    Neurocrine Biosciences, Inc. reported a net loss of $11.1 million, or $0.13 per share, for the third quarter of 2017, compared with a net loss of $36.9 million, or $0.43 per share, in the third quarter of 2016. Total revenues were $60.8 million for the quarter, including net product sales of $45.8 million for INGREZZA (valbenazine), which was approved by the FDA on April 11, 2017 for tardive dyskinesia and launched commercially in late April and May 2017, and $15.0 million in development event-based payments from Mitsubishi Tanabe. For the nine months ended September 30, 2017, the company reported a net loss of $149.4 million, or $1.70 per share, on total revenues of $67.1 million, with sales, general and administrative expense rising to $113.6 million, largely due to the INGREZZA launch. At September 30, 2017, cash, cash equivalents and investments totaled $721.3 million, compared with $350.8 million at December 31, 2016. The company issued $517.5 million of 2.25% convertible senior notes due 2024 in May 2017, with net proceeds of approximately $502.8 million, and the carrying amount of the notes on the balance sheet was $365.1 million. Net cash used in operating activities was $134.9 million for the nine months ended September 30, 2017. Management states that existing capital resources, together with interest income and future strategic alliance payments, are expected to be sufficient to fund current and projected requirements for at least the next 12 months. Subsequent to quarter end, AbbVie notified the company that the FDA accepted the elagolix NDA for filing, which triggers a $30 million event-based payment to the company in the fourth quarter of 2017. The company also disclosed that its three largest customers accounted for all of its product revenue for the quarter, that it relies on a single source supplier for each of INGREZZA's production and active pharmaceutical ingredient, and that Teva received approval for Austedo to treat tardive dyskinesia in August 2017.

    Nov 1, 2017
  29. 2017-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2017

    Neurocrine Biosciences, Inc. filed this Form 10-Q for the quarter ended June 30, 2017, reporting its first quarter of commercial activity following FDA approval of INGREZZA (valbenazine) for tardive dyskinesia on April 11, 2017. Net product sales were $6.3 million for both the three and six months ended June 30, 2017, with no product sales in the prior-year periods. The company reported a net loss of $60.0 million ($0.68 per share) for the second quarter of 2017, compared with $40.3 million ($0.46 per share) a year earlier, and a six-month net loss of $138.3 million ($1.58 per share) versus $59.5 million ($0.69 per share). Total operating expenses rose to $63.6 million in the quarter and $143.5 million for the six months, driven mainly by commercial launch spending, with selling, general and administrative expense reaching $41.7 million in the quarter from $15.0 million a year earlier. Six-month R&D expense of $73.8 million included a $30 million upfront license fee paid to BIAL for opicapone, expensed as in-process R&D. The balance sheet strengthened substantially during the period. In May 2017 the company issued $517.5 million of 2.25% convertible senior notes due 2024, with net proceeds of approximately $502.8 million. At June 30, 2017, cash, cash equivalents and investments totaled $730.8 million, compared with $350.8 million at December 31, 2016, and long-term debt was $360.7 million net of discounts and deferred financing costs. Net cash used in operating activities was $125.6 million for the first six months of 2017. The company stated that its existing capital resources and expected payments under strategic alliances will be sufficient to fund its requirements for at least the next 12 months. The filing also highlights concentration and execution risks. All product sales in the quarter were made to a limited number of select pharmacies and one select distributor, and the company's three largest customers accounted for all product revenue. Neurocrine relies on single-source suppliers for INGREZZA capsules and active pharmaceutical ingredient, has no manufacturing facilities, and carries ongoing FDA post-marketing commitments. It is also a defendant in a Mount Sinai breach-of-license lawsuit seeking unspecified damages, which the company says it intends to defend vigorously.

    Aug 3, 2017
  30. 2017-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2017

    Neurocrine Biosciences, Inc. reported a net loss of $78.3 million, or $0.90 per share, for the first quarter of 2017, compared with a net loss of $19.3 million, or $0.22 per share, in the first quarter of 2016. The company recorded no revenue in the quarter, versus $15.0 million of license fees and milestones in the prior-year period. Total operating expenses rose to $79.9 million from $35.9 million, driven mainly by a $30 million in-process research and development charge for the upfront license fee paid to BIAL for opicapone, and by higher general and administrative spending tied to INGREZZA commercial launch preparation. Cash, cash equivalents and investments totaled $273.3 million at March 31, 2017, down from $350.8 million at December 31, 2016, and net cash used in operating activities was $77.4 million. The filing notes that the FDA approved INGREZZA (valbenazine) for tardive dyskinesia in April 2017, with the full commercial launch occurring on May 1, 2017 and a field-based sales team of approximately 160 personnel. Subsequent to quarter-end, in May 2017, the company issued $517.5 million aggregate principal amount of 2.25% Convertible Senior Notes due 2024, with an initial conversion price of approximately $75.92 per share. The company states that existing capital resources, together with interest income and future strategic alliance payments, will be sufficient to fund its requirements for at least the next 12 months, and it expects to remain unprofitable for the year ending December 31, 2017. The filing also discloses an ongoing lawsuit filed by Icahn School of Medicine at Mount Sinai alleging breach of a license agreement in connection with the AbbVie GnRH collaboration. The company states it believes it has meritorious defenses but cannot predict the outcome or estimate potential loss.

    May 9, 2017
  31. 2016-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2016

    Neurocrine Biosciences, Inc. reported a net loss of $36.9 million, or $0.43 per share, for the third quarter ended September 30, 2016, compared with a net loss of $34.4 million, or $0.40 per share, in the same period of 2015. The company recorded no revenue in the quarter. Operating expenses rose to $38.4 million from $35.8 million, driven mainly by general and administrative expense of $17.5 million versus $11.5 million, reflecting external market research, commercial launch preparation and sales and marketing personnel for INGREZZA. For the first nine months of 2016, revenue was $15.0 million, a $15 million milestone from AbbVie triggered by the start of Phase III development of elagolix in uterine fibroids, and the net loss was $96.4 million, or $1.11 per share, versus $59.6 million, or $0.71 per share, a year earlier. The balance sheet shows cash, cash equivalents and investments of $383.2 million at September 30, 2016, down from $461.7 million at December 31, 2015. Net cash used in operating activities was $74.6 million for the nine months, compared with $22.8 million in 2015. The company's New Drug Application for INGREZZA in tardive dyskinesia has been filed with the FDA, with a PDUFA target date of April 11, 2017. Management states that existing capital resources, together with interest income and future strategic alliance payments, are expected to be sufficient for at least the next 12 months, though the company notes it may need additional funding and that any equity financing would be dilutive. The filing also discloses a lawsuit by Icahn School of Medicine at Mount Sinai alleging that the AbbVie collaboration breached a GnRH receptor license. The company has filed counterclaims and says it intends to defend vigorously, but cannot predict the outcome or estimate any potential loss.

    Nov 2, 2016
  32. 2016-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2016

    Neurocrine Biosciences, Inc. reported a net loss of $40.3 million, or $0.46 per share, for the second quarter of 2016, compared with a net loss of $24.0 million, or $0.28 per share, in the same period of 2015. For the six months ended June 30, 2016, the net loss was $59.5 million, or $0.69 per share, versus $25.2 million, or $0.30 per share, a year earlier. Revenue for the quarter was zero. For the six months, revenue was $15.0 million, all from the milestone payment triggered when AbbVie initiated Phase III development of elagolix in uterine fibroids, compared with $19.8 million of license fees from Mitsubishi Tanabe in the prior-year period. Research and development expense rose to $26.9 million in the quarter from $18.7 million, and general and administrative expense rose to $15.0 million from $6.6 million, driven by VMAT2 Phase III activity, anticipated valbenazine NDA preparation for tardive dyskinesia, and commercial launch preparation. As of June 30, 2016, cash, cash equivalents and investments totaled $414.6 million, compared with $461.7 million at December 31, 2015. Net cash used in operating activities was $43.5 million for the first six months of 2016, versus $4.2 million a year earlier. The company states that its existing capital resources, together with interest income and future payments under its strategic alliances, will be sufficient to fund its current and projected requirements for at least the next 12 months. The company also states it expects to remain unprofitable for the year ending December 31, 2016. Its two lead late-stage programs are elagolix, partnered with AbbVie, and valbenazine, with Mitsubishi Tanabe holding rights in Japan and select Asian markets. The filing also discloses a lawsuit filed by Icahn School of Medicine at Mount Sinai in December 2015 alleging that the AbbVie collaboration breached a license agreement. The company has filed an answer and counterclaims and states it is unable to predict the outcome or estimate any potential loss. The company has never obtained regulatory approval for a drug, and its accumulated deficit was $974.8 million at June 30, 2016 on the balance sheet.

    Aug 3, 2016
  33. 2016-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2016

    Neurocrine Biosciences, Inc. reported a first-quarter 2016 net loss of $19.3 million, or $0.22 per share, compared with a net loss of $1.2 million, or $0.01 per share, in the first quarter of 2015. Total revenues were $15.0 million, consisting of a $15 million development event-based payment from AbbVie triggered by the initiation of Phase III development of elagolix in uterine fibroids, versus $19.8 million of license fee revenue from the Mitsubishi Tanabe agreement in the prior-year quarter. Total operating expenses rose to $35.9 million from $22.1 million, driven by research and development expense of $23.9 million (up from $16.6 million) and general and administrative expense of $12.0 million (up from $5.5 million). The company's balance sheet showed cash, cash equivalents and investments of $431.0 million at March 31, 2016, compared with $461.7 million at December 31, 2015. Net cash used in operating activities was $29.2 million in the quarter, versus $18.2 million a year earlier. Management states that existing capital resources, together with interest income and future payments under strategic alliances, will be sufficient to fund current and projected requirements for at least the next 12 months, and notes that the company expects to incur operating cash flow losses for the foreseeable future. The filing also discloses a December 2015 complaint by Icahn School of Medicine at Mount Sinai alleging that the company's AbbVie collaboration breached a 1999 license agreement; the company has filed a motion to dismiss, which is pending, and states it cannot predict the outcome. The company cites expanded R&D efforts, including the VMAT2 Phase III program and anticipated valbenazine NDA filing for tardive dyskinesia, and pre-commercialization activities as drivers of higher spending.

    May 5, 2016
  34. 2015-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2015

    Neurocrine Biosciences, Inc. reported a net loss of $34.4 million, or $0.40 per share, for the third quarter of 2015 and a net loss of $59.6 million, or $0.71 per share, for the nine months ended September 30, 2015. The company recorded no revenue in the quarter; nine-month revenue was $19.8 million, all from the up-front license fee under its March 31, 2015 collaboration with Mitsubishi Tanabe for NBI-98854 in Japan and other select Asian markets. Operating expenses rose to $35.8 million in the quarter from $16.9 million a year earlier, driven by external VMAT2 Phase III development costs and $8.3 million of performance-based RSU expense recognized in the third quarter as the Phase III Kinect 3 results made the performance conditions probable of being met. The balance sheet strengthened substantially. Cash, cash equivalents and investments totaled $478.8 million at September 30, 2015, compared with $231.3 million at December 31, 2014, following a February 2015 public offering of 8.0 million shares at $36.00 per share that generated net proceeds of approximately $270.7 million. Total stockholders' equity rose to $446.9 million. The company stated that its existing capital resources, together with interest income and future alliance payments, should be sufficient to fund its current and projected requirements for at least the next 12 months. The filing highlights continued dependence on partners. AbbVie holds rights to elagolix, a GnRH antagonist in Phase III development for endometriosis, with $500 million of future event-based payments outstanding, none of which the company classifies as milestones under current accounting guidance. The company also suspended two planned clinical studies of its CRF antagonist NBI-77860 during the second quarter of 2015 due to previously unobserved pre-clinical findings.

    Oct 29, 2015
  35. 2015-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2015

    Neurocrine Biosciences, Inc. filed its Form 10-Q for the quarter ended June 30, 2015 on July 29, 2015. The company, which describes itself as discovering and developing pharmaceuticals for neurological and endocrine-based diseases, reported a net loss of $24.0 million ($0.28 per share) for the second quarter of 2015, compared with $13.4 million ($0.18 per share) a year earlier. For the six months ended June 30, 2015, net loss was $25.2 million, essentially flat with the prior-year period of $25.2 million, as $19.8 million of license fee revenue from the March 2015 Mitsubishi Tanabe agreement offset higher operating expenses. Total operating expenses rose to $47.4 million for the six months from $27.1 million, driven largely by the VMAT2 Phase III program and personnel costs. The balance sheet strengthened considerably. Cash, cash equivalents and investments totaled $498.9 million at June 30, 2015, up from $231.3 million at December 31, 2014, primarily reflecting net proceeds of approximately $270.7 million from a February 2015 public offering of 8.0 million shares at $36.00 per share. Net cash used in operating activities was $4.2 million for the first half, compared with $19.7 million a year earlier, helped by the $30 million up-front payment from Mitsubishi Tanabe. The company stated that existing capital resources, together with interest income and future strategic alliance payments, are expected to be sufficient for at least the next 12 months. Key pipeline items include elagolix, a GnRH antagonist partnered with AbbVie that is in Phase III development for endometriosis and Phase II for uterine fibroids, with $500 million in future event-based payments outstanding under that agreement. The company's VMAT2 inhibitor, NBI-98854, is in Phase III development for tardive dyskinesia. During the quarter, Neurocrine suspended two planned clinical studies of its CRF antagonist NBI-77860 due to previously unobserved pre-clinical findings. The filing also notes $10.2 million of the Mitsubishi Tanabe up-front payment is deferred for recognition in future periods.

    Jul 29, 2015
  36. 2015-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2015

    Neurocrine Biosciences, Inc. reported a net loss of $1.2 million, or $0.01 per share, for the quarter ended March 31, 2015, compared with a net loss of $11.8 million, or $0.17 per share, in the same period of 2014. The improvement was driven primarily by $19.8 million of license fee revenue recognized from the up-front payment under the March 31, 2015 collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation for NBI-98854. Operating expenses rose to $22.1 million from $12.7 million, with research and development expense increasing to $16.6 million from $8.6 million, mainly due to external development costs for the VMAT2 Phase III program. The company's balance sheet strengthened significantly. Cash, cash equivalents and investments totaled $485.5 million at March 31, 2015, versus $231.3 million at December 31, 2014, following a February 2015 public offering of 8.0 million shares at $36.00 per share that generated approximately $270.7 million in net proceeds. Stockholders' equity rose to $484.7 million from $208.7 million. The company stated that its existing capital resources, together with interest income and future payments under its strategic alliances, will be sufficient to fund its requirements for at least the next 12 months. The filing also notes that Neurocrine has an accumulated deficit of $827.5 million at March 31, 2015, does not expect to be profitable or generate positive operating cash flow in 2015, and has no approved products. Its strategy depends heavily on its collaboration with AbbVie for elagolix, under which $500 million of future event-based payments remained outstanding at quarter end, and on the new Mitsubishi Tanabe agreement, of which $10.2 million of the $30 million up-front payment was deferred.

    Apr 30, 2015
  37. 2014-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2014

    Neurocrine Biosciences, Inc. filed this Form 10-Q for the quarter ended September 30, 2014. The company reported no revenue for the third quarter of 2014 (compared with $729 thousand in the third quarter of 2013) and a net loss of $15.9 million, or $0.21 per share, versus a net loss of $11.1 million, or $0.17 per share, a year earlier. For the nine months, the net loss was $41.1 million, or $0.56 per share, compared with $35.4 million, or $0.53 per share, in the prior-year period. Total operating expenses rose to $16.9 million in the quarter from $12.7 million, driven by higher research and development and general and administrative costs. The company stated that it has not generated revenue from product sales and expects operating losses to continue. The balance sheet strengthened over the period. Cash, cash equivalents and investments totaled $246.8 million at September 30, 2014, compared with $145.7 million at December 31, 2013, largely reflecting net proceeds of approximately $133.2 million from a February 2014 public offering of 8.0 million shares at $17.75 per share. Stockholders' equity rose to $224.0 million from $120.4 million. Net cash used in operating activities was $31.8 million for the first nine months of 2014. The company's two lead late-stage programs are elagolix, a GnRH antagonist partnered with AbbVie Inc. and in Phase III development for endometriosis, and a wholly owned VMAT2 inhibitor for which Phase III development in tardive dyskinesia was recently initiated. The company said its existing capital resources are expected to be sufficient for at least the next 12 months, while noting that additional funding may be needed and that future equity financings would be dilutive.

    Nov 4, 2014
  38. 2014-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2014

    Neurocrine Biosciences, Inc. reported a net loss of $13.4 million, or $0.18 per share, for the second quarter of 2014, compared with a net loss of $12.2 million, or $0.18 per share, in the second quarter of 2013. For the first half of 2014, the net loss was $25.2 million, or $0.35 per share, versus $24.3 million, or $0.36 per share, a year earlier. The company reported no revenue in the second quarter or first half of 2014, compared with $0.7 million and $1.5 million in the same periods of 2013, and total operating expenses were $14.4 million for the quarter and $27.1 million for the six months. Research and development expense for the first half of 2014 was $18.7 million, down from $20.8 million, mainly due to lower VMAT2 external development costs after Phase IIb work finished in 2013. The company states it expects VMAT2 to enter Phase III development later in 2014, which it expects to significantly increase external development expenses. The balance sheet strengthened substantially. At June 30, 2014, cash, cash equivalents and investments totaled $259.9 million, compared with $145.7 million at December 31, 2013. The increase reflects a February 2014 public offering of 8.0 million shares at $17.75 per share, which generated net proceeds of approximately $133.2 million. Net cash used in operating activities was $19.7 million for the first half of 2014. Stockholders' equity rose to $236.8 million from $120.4 million at year-end 2013. The company believes its existing capital resources, together with interest income and future payments under its strategic alliances, will be sufficient to fund its current and projected requirements for at least the next 12 months. The company's lead programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II for uterine fibroids, partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for movement disorders. The filing notes that AbbVie is responsible for third-party development and commercialization costs for elagolix and that the company is entitled to a percentage of worldwide sales. The company has an accumulated deficit of $790.99 million as of June 30, 2014 and states it does not expect to be profitable for the year ending December 31, 2014 or the foreseeable future.

    Aug 6, 2014
  39. 2014-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2014

    Neurocrine Biosciences, Inc. reported a net loss of $11.8 million, or $0.17 per share, for the quarter ended March 31, 2014, compared with a net loss of $12.1 million, or $0.18 per share, in the first quarter of 2013. The company has not generated product revenue; total revenues were zero in the quarter versus $730 thousand a year earlier. Research and development expense fell to $8.6 million from $10.3 million, primarily due to lower external development costs for the VMAT2 program after it substantially completed Phase IIb development in 2013. General and administrative expense rose to $4.2 million from $3.4 million, largely from higher share-based compensation. The balance sheet strengthened significantly. In February 2014 the company sold 8.0 million shares at $17.75 per share, with net proceeds of about $133.2 million. Cash, cash equivalents and investments totaled $271.2 million at March 31, 2014, compared with $145.7 million at December 31, 2013. Management believes existing capital resources, interest income and future alliance payments will be sufficient for at least the next 12 months, while stating that additional funding may be needed and that future equity financings would be dilutive. Pipeline and collaboration news is central to the outlook. The company's lead programs are elagolix, a GnRH antagonist partnered with AbbVie and in Phase III development for endometriosis, and a wholly owned VMAT2 inhibitor for movement disorders. The company anticipates VMAT2 entering Phase III later in 2014, which the filing says will significantly increase external development expenses. The accumulated deficit was $777.6 million at March 31, 2014.

    May 1, 2014
  40. 2013-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2013

    Neurocrine Biosciences, Inc. reported a net loss of $11.1 million, or $0.17 per share, for the third quarter of 2013, compared with a net loss of $3.1 million, or $0.05 per share, in the same period of 2012. Total revenues fell to $0.7 million from $9.4 million, primarily because the collaborative development portion of the AbbVie agreement for elagolix concluded as scheduled on December 31, 2012. For the nine months ended September 30, 2013, the net loss was $35.4 million, or $0.53 per share, versus $4.5 million, or $0.07 per share, a year earlier, as revenues dropped to $2.2 million from $31.2 million and R&D expense rose to $30.3 million, driven by the VMAT2 Phase IIb program. At September 30, 2013, cash, cash equivalents and investments totaled $157.6 million, compared with $173.5 million at December 31, 2012, and the accumulated deficit reached $755.1 million. Management states that existing capital resources, together with interest income and future payments under strategic alliances, will be sufficient to fund current and projected requirements for at least the next 12 months. The company also notes it has effective shelf registration statements allowing issuance of up to $187 million of common stock, and that it expects operating cash flow losses for the foreseeable future. The company describes itself as a clinical stage drug discovery company focused on neurological and endocrine diseases, with two lead late-stage programs: elagolix, a GnRH antagonist partnered with AbbVie Inc. for women's health, and a wholly owned VMAT2 inhibitor for movement disorders. The filing reports eleven programs in research and development, including six in clinical development.

    Oct 29, 2013
  41. 2013-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2013

    Neurocrine Biosciences, Inc. reported a net loss of $12.2 million ($0.18 per share) for the second quarter of 2013 and $24.3 million ($0.36 per share) for the first half of 2013, compared with net losses of $0.5 million and $1.4 million in the same periods of 2012. Revenue fell sharply to $0.7 million for the quarter and $1.5 million for the six months, down from $10.6 million and $21.8 million a year earlier, as the collaborative development portions of the AbbVie (elagolix) and Boehringer Ingelheim (GPR119) agreements concluded in December 2012 and June 2012, respectively. Research and development expense rose to $10.5 million in the quarter and $20.8 million for the six months, driven mainly by external development costs for the VMAT2 program in Phase IIb development. At June 30, 2013, the company had cash, cash equivalents and investments of $166.4 million, compared with $173.5 million at December 31, 2012, and an accumulated deficit of $744.0 million. Total stockholders' equity was $136.0 million. Management states that existing capital resources, interest income and future alliance payments should be sufficient to fund current and projected requirements for at least the next 12 months, while acknowledging that additional equity or debt financing may be needed and that equity financings would be dilutive. The company also has effective shelf registration statements allowing issuance of up to $187 million in common stock. The company describes itself as a clinical-stage drug discovery company focused on neurological and endocrine diseases, with elagolix (a GnRH antagonist partnered with AbbVie) and a wholly owned VMAT2 inhibitor as its two lead late-stage programs. The company has not generated product revenue to date, and management expects operating losses to continue for the foreseeable future.

    Jul 26, 2013
  42. 2013-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2013

    Neurocrine Biosciences, Inc. reported a net loss of $12.1 million, or $0.18 per share, for the first quarter ended March 31, 2013, compared with a net loss of $0.9 million, or $0.01 per share, in the same period of 2012. Total revenues fell to $0.7 million from $11.3 million, primarily because the collaborative development portion of the AbbVie agreement for elagolix concluded on December 31, 2012, and the sponsored research portion of the Boehringer Ingelheim GPR119 collaboration was completed in June 2012. Research and development expense rose to $10.3 million from $9.4 million, driven mainly by external development spending on the VMAT2 program, which is in Phase IIb development. General and administrative expense decreased to $3.4 million from $3.7 million. Liquidity declined over the quarter. Cash and cash equivalents fell to $31.6 million at March 31, 2013 from $63.8 million at December 31, 2012, while short-term and long-term investments rose, leaving cash, cash equivalents and investments at $175.6 million versus $173.5 million at year-end 2012. Operating cash flow was positive at $1.9 million, aided by the collection of $14.1 million in receivables under collaboration agreements that was outstanding at year-end. The accumulated deficit reached $731.7 million, and the company states it believes existing capital resources and alliance payments will be sufficient for at least the next 12 months. The filing also notes approximately $187 million of effective shelf registration capacity, of which about $37 million remained available under the December 2010 shelf, and it lists the lead program elagolix, partnered with AbbVie, as in Phase III for endometriosis. The company states it has eleven programs in research and development, six of them in clinical development.

    May 2, 2013
  43. 2012-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2012

    Neurocrine Biosciences, Inc. reported a net loss of $3.1 million, or $(0.05) per share, for the third quarter ended September 30, 2012, compared with net income of $31.4 million in the same period of 2011. Total revenues for the quarter were $9.4 million (in millions, $9,357 thousand), down from $41.6 million a year earlier, primarily because two Abbott milestones totaling $30.0 million were achieved in Q3 2011. For the nine months, the company reported a net loss of $4.5 million, or $(0.07) per share, versus net income of $36.2 million in 2011, with revenues of $31.2 million against $66.3 million. Research and development expense rose to $28.1 million for the nine months from $22.9 million, driven mainly by the VMAT2 program in Phase II development. The balance sheet strengthened during the period. Cash, cash equivalents and investments totaled $182.8 million at September 30, 2012, compared with $129.1 million at December 31, 2011, following a January 2012 public offering of 10.9 million shares at $8.10 per share that generated net proceeds of approximately $83.0 million. Stockholders' equity increased to $143.3 million from $60.1 million, and the accumulated deficit stood at $729.2 million. The company states that its existing capital resources, together with interest income and future alliance payments, are sufficient to fund current plans for at least the next 12 months. The filing highlights continued dependence on collaborations. Abbott's agreement covers the lead clinical program, elagolix, for endometriosis and uterine fibroids, and Boehringer Ingelheim's GPR119 collaborative research period ended in June 2012. The company also notes that indiplon's future is uncertain following a 2007 FDA approvable letter, and that it expects operating and cash flow losses to continue for the foreseeable future.

    Oct 31, 2012
  44. 2012-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2012

    Neurocrine Biosciences, Inc. reported a net loss of $0.5 million, or $0.01 per share, for the second quarter of 2012 (three months ended June 30, 2012), compared with net income of $2.0 million, or $0.04 per share, in the same period of 2011. For the first half of 2012, the company reported a net loss of $1.4 million, or $0.02 per share, versus net income of $4.9 million, or $0.09 per share, a year earlier. Total revenues were $10.6 million for the quarter and $21.8 million for the six months, both lower than the prior-year periods, primarily due to lower revenue under the Abbott and Boehringer Ingelheim collaborations. Research and development expense rose to $18.2 million for the six months from $15.5 million. The balance sheet strengthened during the period. Cash, cash equivalents and investments totaled $192.2 million at June 30, 2012, up from $129.1 million at December 31, 2011, driven mainly by net proceeds of approximately $83.0 million from a January 2012 public offering of 10.9 million shares at $8.10 per share. The company's accumulated deficit was $726.1 million, and it stated that its existing capital resources, together with interest income and future collaboration payments, are sufficient to fund current and projected requirements for at least the next 12 months. The company's lead clinical program is elagolix, a GnRH antagonist for endometriosis and uterine fibroids partnered with Abbott, which holds final decision-making authority and may terminate the collaboration on 180 days' notice. The company also disclosed that the 2007 FDA approvable letter for indiplon added new requirements, and that it is evaluating alternatives for that program. The Boehringer Ingelheim GPR119 collaborative research period concluded in June 2012, and the Committed Equity Financing Facility with Kingsbridge was set to expire on September 15, 2012, with no shares issued under it as of June 30, 2012.

    Jul 31, 2012
  45. 2012-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2012

    Neurocrine Biosciences, Inc. reported a net loss of $886 thousand, or $(0.01) per share, for the quarter ended March 31, 2012, compared with net income of $2,882 thousand, or $0.05 per share, in the same period of 2011. Total revenues were $11.3 million versus $12.5 million a year earlier, as lower revenue recognition under the Abbott and Boehringer Ingelheim collaborations offset steady amortization of up-front license fees of $9.2 million. Research and development expense rose to $9.4 million from $7.3 million, driven mainly by higher VMAT2 program costs as that program progressed in Phase II, and general and administrative expense increased to $3.7 million from $3.2 million. The balance sheet strengthened considerably during the quarter. Cash, cash equivalents and investments totaled $200.1 million at March 31, 2012, up from $129.1 million at December 31, 2011, following a January 2012 public offering of 10.9 million shares at $8.10 per share that generated net proceeds of approximately $83.0 million. Stockholders' equity rose to $143.8 million from $60.1 million, and the accumulated deficit stood at $725.6 million. Net cash used in operating activities was $11.2 million for the quarter. The company stated that its existing capital resources, together with interest income and future payments under its strategic alliances, are expected to be sufficient for at least the next 12 months. The filing also notes that the Phase II trial of 561679 in patients with a major depressive episode showed no benefit compared with placebo, and that the indiplon program remains uncertain following a 2007 FDA approvable letter with new requirements.

    May 2, 2012
  46. 2011-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2011

    Neurocrine Biosciences, Inc. (the Company) reported net income of $31.4 million, or $0.56 per diluted share, for the quarter ended September 30, 2011, compared with net income of $3.3 million, or $0.06 per diluted share, in the same period of 2010. Total revenues for the quarter were $41.6 million versus $14.4 million a year earlier, driven primarily by $30.0 million in milestone revenue from its Abbott collaboration on elagolix ($10.0 million tied to advancing elagolix into Phase II uterine fibroids trials and $20.0 million tied to an FDA pre-Phase III meeting for endometriosis). For the nine months, net income was $36.2 million, or $0.64 per diluted share, versus a net loss of $10.5 million a year earlier, and the Company noted that operating cash flow was negative $11.7 million compared with positive $54.5 million in the prior-year period, reflecting the timing of upfront license fees received in 2010. As of September 30, 2011, cash, cash equivalents and investments totaled $116.7 million, down from $130.6 million at December 31, 2010, and total stockholders' equity was $57.7 million. The Company stated it has an accumulated deficit of $726.0 million, expects to be profitable for 2011 but not to be operating cash flow positive in 2011, and believes existing resources are sufficient for at least the next 12 months. It also disclosed an effective shelf registration for up to $125 million and a Committed Equity Financing Facility with Kingsbridge Capital Limited for up to $75 million, under which no shares had been issued as of September 30, 2011. The pipeline includes eleven programs, six in clinical development, with elagolix (endometriosis and uterine fibroids) as the lead program partnered with Abbott. The filing also flags that a Phase II trial of CRF1 antagonist 561679 in major depressive episode showed no benefit versus placebo, and that the indiplon NDA faces additional FDA requirements following a December 2007 approvable letter, with development activities ceased in the United States.

    Oct 31, 2011
  47. 2011-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2011

    Neurocrine Biosciences, Inc. reported net income of $1,976 thousand ($0.04 per diluted share) for the three months ended June 30, 2011, compared with a net loss of $5,152 thousand ($0.09 per share) in the same period of 2010. For the six months ended June 30, 2011, net income was $4,858 thousand ($0.09 per diluted share), versus a net loss of $13,788 thousand in 2010. Total revenues were $12,157 thousand for the quarter and $24,669 thousand for the six months, driven mainly by collaboration revenue from the Abbott International Luxembourg S.à r.l. agreement covering elagolix and other GnRH compounds and the Boehringer Ingelheim agreement covering GPR119 agonists, both entered into in June 2010. Research and development expense was $8,176 thousand for the quarter and $15,493 thousand for the six months. The balance sheet shows cash, cash equivalents and investments totaling $115.2 million at June 30, 2011, down from $130.6 million at December 31, 2010, with an accumulated deficit of $757.4 million and total stockholders' equity of $25,558 thousand. Operating cash flow was negative $14,490 thousand for the first half of 2011, compared with positive $53,330 thousand in the prior-year period, a change the company attributes primarily to the $75 million Abbott upfront payment received in 2010. The company states it believes existing resources and future alliance payments will be sufficient for at least the next 12 months. The filing also updates risk factors. The company says a Phase II trial of its CRF1 antagonist 561679 in major depressive episode showed no benefit compared with placebo. It states that the FDA's 2007 approvable letter for indiplon imposed new requirements, and that the company ceased indiplon clinical development in the United States. The company has a shelf registration for up to $125 million and a Committed Equity Financing Facility with Kingsbridge Capital Limited for up to $75 million, but had not issued any shares under the facility as of June 30, 2011.

    Jul 29, 2011
  48. 2011-Q1

    Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2011

    Neurocrine Biosciences, Inc. reported net income of $2.9 million, or $0.05 per diluted share, for the first quarter of 2011, compared with a net loss of $8.6 million, or $(0.19) per share, in the same period of 2010. Total revenues rose to $12.5 million from $0.8 million, driven mainly by collaboration revenue from Abbott International Luxembourg S.à r.l. ($10.1 million) and Boehringer Ingelheim ($1.6 million). The company attributes the improvement to revenue recognized under its June 2010 collaborations with Abbott (elagolix and GnRH compounds) and Boehringer Ingelheim (GPR119 agonists). Milestones and license fees were $9.2 million, while research and development expense was $7.3 million and general and administrative expense was $3.2 million. The balance sheet shows liquidity declining over the quarter. Cash, cash equivalents and investments totaled $121.6 million at March 31, 2011, versus $130.6 million at December 31, 2010, and cash used in operating activities was $8.6 million. Total stockholders' equity was $23.0 million, and deferred revenues totaled $64.9 million across current and long-term portions. The accumulated deficit stood at $759.4 million. The company states that existing capital resources are sufficient for at least the next 12 months, and it has a $125 million shelf registration and a Committed Equity Financing Facility with Kingsbridge Capital Limited of up to $75 million, with no shares issued under the facility as of March 31, 2011. Management expects to be profitable for the full year 2011 but does not expect to be operating cash flow positive in 2011 or to remain profitable beyond 2011. The filing also notes that a Phase II trial of CRF1 antagonist 561679 in major depressive episode showed no benefit versus placebo, and that the FDA's 2007 approvable letter for indiplon imposed new requirements, leaving its future development uncertain.

    May 3, 2011
  49. 2010-Q3

    Neurocrine Biosciences Quarterly Report for Q3 Ended Sep 30, 2010

    Neurocrine Biosciences, Inc. reported net income of $3.3 million, or $0.06 per diluted share, for the third quarter ended September 30, 2010, compared with a net loss of $8.2 million, or $0.21 per share, in the same period of 2009. Total revenues rose to $14.4 million from $0.7 million, driven by the collaboration agreements with Abbott and Boehringer Ingelheim. For the nine months, the net loss narrowed to $10.5 million, or $0.20 per share, from $43.1 million, or $1.11 per share, a year earlier. Revenues for the nine months were $19.8 million versus $2.2 million. The balance sheet strengthened substantially. Cash, cash equivalents and investments totaled $135.2 million at September 30, 2010, up from $59.9 million at December 31, 2009, reflecting the $75.0 million Abbott upfront payment, the $10.0 million Boehringer Ingelheim upfront payment, and net proceeds of approximately $21.4 million from a March 2010 public offering. Deferred revenues rose to $36.96 million current and $46.4 million non-current, and stockholders' equity increased to $16.6 million from $4.0 million. The company stated it does not expect to be profitable for the full year 2010 and reported an accumulated deficit of $764.8 million. Management believes existing capital resources, interest income and future alliance payments will be sufficient for at least the next 12 months, but notes it will need additional funding for its programs. The filing highlights risks including the uncertain future of indiplon following a 2007 FDA approvable letter with new requirements, the lead elagolix program's dependence on FDA acceptance of endpoints, a Phase II failure of GSK561679 in major depressive episode, and dilution from the Kingsbridge committed equity facility.

    Oct 29, 2010
  50. 2010-Q2

    Neurocrine Biosciences Quarterly Report for Q2 Ended Jun 30, 2010

    Neurocrine Biosciences, Inc. reported a net loss of $5.2 million, or $0.09 per share, for the three months ended June 30, 2010, compared with $15.3 million, or $0.39 per share, in the same period of 2009. For the six months ended June 30, 2010, the net loss was $13.8 million, or $0.27 per share, versus $34.9 million, or $0.90 per share, a year earlier. Total revenues rose to $4.6 million for the quarter and $5.4 million for the six months, driven by the recently executed collaborations with Abbott and Boehringer Ingelheim for the GnRH and GPR119 programs. Operating expenses fell, with research and development expense of $7.3 million for the quarter versus $10.8 million a year earlier, reflecting the restructuring program implemented in the second quarter of 2009. The balance sheet strengthened considerably. Cash, cash equivalents, and investments totaled $134.3 million at June 30, 2010, compared with $59.9 million at December 31, 2009. The increase was driven primarily by a $75.0 million upfront payment from Abbott and approximately $21.4 million in net proceeds from a March 2010 public offering of common stock. Deferred revenues rose to $36.95 million current and $55.6 million non-current, and total stockholders' equity increased to $12.4 million from $4.0 million. The company stated that existing capital resources and future alliance payments are sufficient to fund its requirements for at least the next 12 months. The filing also highlights ongoing risks. The company has an accumulated deficit of $768 million and expects to incur operating losses in the near future. It holds $12.3 million par value of auction rate securities, $9.1 million of which was sold to UBS at par on July 1, 2010. The indiplon program remains uncertain following a 2007 FDA approvable letter, and the company has a Committed Equity Financing Facility with Kingsbridge Capital Limited of up to $75 million, with no shares issued under it as of June 30, 2010.

    Jul 29, 2010